Concourse Financial Group Securities’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Concourse Financial Group Securities’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19	Closed	-$912	–	2478
2021 Q4	$1K	Hold	19	–	–	﹤0.01%	2346
2021 Q3	$1K	Sell	19 -5	-21%	-$246	﹤0.01%	2375
2021 Q2	$1K	Hold	24	–	–	﹤0.01%	2334
2021 Q1	$1K	Buy	24 +6	+33%	+$279	﹤0.01%	2306
2020 Q4	$1K	Buy	+18	New	+$842	﹤0.01%	2254
2020 Q2	–	Sell	-40	Closed	-$2K	–	2302
2020 Q1	$2K	Hold	40	–	–	﹤0.01%	1955
2019 Q4	$2K	Hold	40	–	–	﹤0.01%	1948
2019 Q3	$2K	Hold	40	–	–	﹤0.01%	1593
2019 Q2	$2K	Hold	40	–	–	﹤0.01%	2050
2019 Q1	$2K	Buy	+40	New	+$1.78K	﹤0.01%	2081

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SGCIA

Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Concourse Financial Group Securities's EGRX Position: Q1 2022 in Review

Concourse Financial Group Securities sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 19 shares — an estimated $912 sold.

Concourse Financial Group Securities first reported a position in EGRX in Q1 2019 and held it in 10 quarters. The position peaked at $2K in Q1 2020. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

Concourse Financial Group Securities reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
Concourse Financial Group Securities sold 19 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $912.
Concourse Financial Group Securities first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 10 quarters.
Concourse Financial Group Securities's Eagle Pharmaceuticals, Inc. position peaked at $2K in Q1 2020.
160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Concourse Financial Group Securities's 13F filing for Q1 2022, filed 9 May 2022.